key: cord-0686150-0nli43em
authors: Kenig, Ariel; Ishay, Yuval; Kharouf, Fadi; Rubin, Limor
title: Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products
date: 2021-04-07
journal: Clin Immunol
DOI: 10.1016/j.clim.2021.108723
sha: 919ea52f853c664b2042eb3828d756d57401ad1c
doc_id: 686150
cord_uid: 0nli43em

Severe acute respiratory syndrome coronavirus 2 infected patients, receiving background anti-CD20 therapy, were treated with convalescent plasma or plasma-based products. Eight patients were included in the study, presenting with prolonged disease course and delayed viral clearance. CP/plasma-based products were offered as an add-on therapy to standard medical treatment. All patients showed remarkable clinical and laboratory improvement. In addition, polymerase chain reaction from nasopharyngeal swabs rapidly converted to negative following plasma administration. This study emphasizes the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion.

In the inevitable race to mitigate the coronavirus disease 2019 (COVID-19) burden, therapies for acute infection proved no significant efficacy in comparison to vaccination and infection control measures. While many treatments showed initial promise, only glucocorticoid therapy have held to the scrutiny of thorough research (1) .

Passive immune therpy is a historically accepted therapeutic approach for the immediate management of viral infections. Relying on previous experience with several viral infections, including influenza and Ebola virus, therapy with convalescent plasma (CP) was utilized in the current pandemic (2, 3) . As for now, only low-quality evidence supports its routine use (4, 5) . Moreover, scarce evidence is available regarding the efficacy in B-cell depleted patients, secondary to anti-CD20 therapy.

Immunocompromised patients are prone to develop a prolonged disease course, persistent symptoms, severe manifestations, and decreased viral clearance (6, 7) . Herein, we present eight patients with refractory COVID-19, secondary to iatrogenic B-cell depletion. Besides the similarity in disease characteristics, all patients showed a favorable response to the administration of CP, resulting in clinical and laboratory improvement and successful viral clearance.

Study subjects included were immunocompromised adult (age >18 years) patients hospitalized at Hadassah Medical Center, between April 2020 to February 2021, with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, J o u r n a l P r e -p r o o f diagnosed based on clinical symptoms and nasal swabs, testing positive for realtime reverse transcriptase-polymerase chain reaction (PCR) assay for SARS-CoV-2.

Immunosuppression was secondary to the administration of anti-CD20 biological agents: Rituximab (RTX), Obinutuzumab or Oceralizumab, for the patients' background hematologic or autoimmune disorders.

CP/plasma-based products were offered as an add-on therapy to standard medical treatment: Antiviral therapy (Remdesivir), anticoagulation (LMWH), empiric antibiotics, and/or glucocorticoid therapy. All patients signed informed consent prior to plasma administration. 

Since the beginning of the COVID-19 pandemic, a cohort of eight patients receiving anti-B-cell therapies were treated in our institution with convalescent plasma or plasma-based products (Table 1) . admitted for further evaluation. Initially, she was empirically treated with ertapenem and azithromycin for the coverage of a suspected bacterial superinfection. However, a thorough assessment, including physical examination, blood, urine, and sputum cultures, as well as a whole-body CT scan, was significant only for pulmonary ground glass opacities (GGO), compatible with COVID-19. Serologic testing for SARS-CoV-2 was negative, suggesting an unresolved SARS-CoV-2 infection.

Therefore, two doses of CP were added to background therapy with Remdesivir and LMWH. Soon thereafter, remarkable clinical recovery ensued, with complete defervescence C-reactive protein decreased from 18.8 mg/dL on the day of plasma administration to 1.1 mg/dL, 72 hours later. PCR-based nasopharyngeal swabs, being positive for 45 days, converted to negative within 2 days.

A 64-year-old female was diagnosed with an asymptomatic COVID-19 after a positive nasopharyngeal swab for SARS-CoV-2. Her medical history was significant for rheumatoid arthritis, treated with RTX and leflunomide. The last rituximab dose was administrated 3 months earlier.

After an asymptomatic course during the first week, she started to suffer from highgrade fever, fatigue, and dyspnea. She was admitted to the hospital for respiratory distress and severe desaturation in room air, with the need for supplemental oxygen through high-flow AIRVO. Her lab tests were notable for lymphopenia, high inflammatory markers, and elevated d-dimer. Serology for SARS-CoV-2 was negative, and chest X-ray (CXR) displayed diffuse alveolar infiltrates.

The patient was initially treated with intravenous methylprednisolone, prophylactic LMWH, and empiric antibiotics (for a presumed bacterial superinfection). At the 4th J o u r n a l P r e -p r o o f day of her hospitalization, and in light of her B-cell depleted status, she received two sequential doses of CP. Within 5 days, pronounced clinical improvement ensued, with resolution of fever and respiratory distress, and a marked decline in the need for supplemental oxygen. Her nasopharyngeal swabs, which were positive for 25 days, turned negative within 10 days of CV administration.

Passive immunotherapy was introduced in the late 19 th century as a potential therapy for a variety of viral infections. Nowadays, it represents a notable and relevant treatment option in the COVID-19 pandemic. While the administration of CP or plasma-based products is indicated regardless of the patient's immunological status, efficacy was proved to be highest upon use in the early stages of COVID-19.

The administration to elderly patients (>65 years old) within 72 hours of symptom onset has achieved a 48% reduction in progression to severe respiratory disease (8) .

In our study, CP/plasma-based products were administrated more than 72 hours of symptom onset, due to the prolonged disease course presented by our immunocompromised hosts. Despite the delay between symptom-onset and administration, remarkable efficacy in clinical and laboratory outcomes was achieved.

Host immune response against viral pathogens is mainly mediated by T-cell lymphocytes and natural killer cells. In addition to their role in humoral immunity and production of neutralizing antibodies, B-cells also serve as professional antigen presenting cells, inducing T-cell activation and differentiation (9) . Hence, humoral J o u r n a l P r e -p r o o f and cellular immunity is affected by anti-CD20 treatment. B-cell depleted patients present with decreased viral clearance and a prolonged disease course.

Plasma therapy has a number of benefits, including the prevention of new infection, antibody-mediated viral suppression, viral clearance, as well as accelerated infectedcell clearance via complement activation, antibody-dependent cellular cytotoxicity (ADCC), and phagocytosis (10) . All of the latter emphasize the potential immunological yield of CP administration as a therapeutical option for B-cell depleted patients.

Notably, B-cell depletion could positively influence disease severity. It results in a reduction of non-neutralizing antibodies, thus posing a decreased risk for developing antibody-dependent enhancement syndrome, cytokine storm, and acute respiratory distress syndrome (7, 11) . Accordingly, depletion in peripheral B-cells results direct reduction of cytokine production, including IL-6. In concordance, most patients in the current study were diagnosed with mild COVID-19, mainly presenting with refractory fever, prolonged disease course, persistent PCR positivity.

We have herein presented our institutional experience with CP/plasma-based product therapy in B-cell depleted immunocompromised patients. Following administration, all patients achieved clinical and laboratory improvement.

Accelerated viral clearance also occurred, as reflected by the accelerated rate of negative nasopharyngeal PCR swabs. No transfusion reaction was documented, indicating evident safety. Study results are aligned with up-to-date reports on safety and efficacy of CP therapy in B cell depleted patients (12) .

Our study holds some limitations. Firstly, the sample size is small. Secondly, patients received additional COVID-19 targeted therapy, such as Remdesivir and J o u r n a l P r e -p r o o f corticosteroids, thus potentially adding to the therapeutic benefit of plasma administration. In addition due to the retrospective aspect of this study, data is lacking regarding anti-SARS-CoV-2 antibodies following CP administration in 50% of patients. Furthermore, anti-SARS-CoV-2 antibodies measurements were performed in different timelines post treatment with CP.

To conclude, anti-CD20 targeted therapies continue to be applied worldwide for a variety of haematological and autoimmune disorders. In the era of the COVID-19 pandemic, patients receiving these therapies are prone to persistent SARS-CoV-2 infection. CP/ plasma-based products offer a safe and effective therapeutic option for such patients. Further evidence is still needed to establish the clinical benefit of such therapy. 

National Institution of Health: Coronavirus Disease 2019 (COVID-19) Treatment Guidelines

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Use of convalescent plasma therapy in SARS patients in Hong Kong

Convalescent plasma is a clutch at straws in COVID-19

management! A systematic review and meta-analysis

Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

The role of B lymphocytes as antigen-presenting cells

Deployment of convalescent plasma for the prevention and treatment of COVID-19

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19